治疗经前综合征的个性化顺势疗法药物:双盲、随机、安慰剂对照试验

IF 16.4 1区 化学 Q1 CHEMISTRY, MULTIDISCIPLINARY
Sanjib Sahoo , Chintamani Nayak , Prasanta Rath , Soumya Bhattacharya , Suranjana Mukherjee , Abhijit Dutta
{"title":"治疗经前综合征的个性化顺势疗法药物:双盲、随机、安慰剂对照试验","authors":"Sanjib Sahoo ,&nbsp;Chintamani Nayak ,&nbsp;Prasanta Rath ,&nbsp;Soumya Bhattacharya ,&nbsp;Suranjana Mukherjee ,&nbsp;Abhijit Dutta","doi":"10.1016/j.explore.2024.103039","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><p>Background: Premenstrual syndrome (PMS) is a common disorder among female population that adversely affects their physical and emotional well-being. Conventional treatments for PMS may have limitations and side effects, prompting a need for complementary therapeutic approaches. This double-blind, randomized, placebo-controlled trial aimed to investigate the efficacy of individualized Homeopathic medicines (IH) in treating PMS symptoms in comparison to placebo (PL).</p></div><div><h3>Methods</h3><p>This study recruited female participants of reproductive age who had been experiencing premenstrual syndrome (PMS) for &gt;3 months, from the Outpatient Department. The participants were randomly assigned to receive either IH or PL. The measured outcomes included the Shortened Premenstrual Assessment Form (SPAF) questionnaire as the primary outcome, and the Premenstrual Tension Syndrome Visual Analogue Scale (PMTS-VAS) and the Premenstrual Tension Syndrome Observer Rating Scale – Revised (PMTS-OR) as secondary outcomes. These measures were assessed at baseline and every month for 3 months.</p></div><div><h3>Results</h3><p>The results showed a statistically significant reduction in total SPAF scores for the IH group compared to the placebo group (<em>F</em> = 11.340; <em>P</em> &lt; 0.001) at month 2 (-5.5 ± 1.8, <em>P</em> = 0.003), and month 3 (-6.6 ± 2.0, <em>P</em> = 0.002). Additionally, there were significant reductions in PMTS-VAS and PMTS-OR scores in the IH compared to placebo group. <em>Natrum muriaticum</em> (<em>n</em> = 4/30, 13.3 %) was the most frequently indicated medicines in the study. Four adverse events (13.33 %) occurred in the IH group, and six adverse events (16.67 %) in the Placebo group, with no serious events reported, and no additional medicinal treatment was required for participants during the study period.</p></div><div><h3>Conclusions</h3><p>Individualized Homeopathic medicines were found to be significantly effective, compared to placebo in reducing PMS symptoms. Further independent replication is warranted to validate and corroborate these findings, as well as to identify the most effective Homeopathic medicines for treating PMS symptoms. Until then, clinicians may consider these findings when exploring personalized and holistic therapeutic strategies for managing PMS.</p></div><div><h3>Trial Registration</h3><p>CTRI/2020/11/028,796, dt. 02/11/2020</p></div>","PeriodicalId":1,"journal":{"name":"Accounts of Chemical Research","volume":null,"pages":null},"PeriodicalIF":16.4000,"publicationDate":"2024-08-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Individualized homeopathic medicines in the treatment of premenstrual syndrome: A double-blind, randomized, placebo-controlled trial\",\"authors\":\"Sanjib Sahoo ,&nbsp;Chintamani Nayak ,&nbsp;Prasanta Rath ,&nbsp;Soumya Bhattacharya ,&nbsp;Suranjana Mukherjee ,&nbsp;Abhijit Dutta\",\"doi\":\"10.1016/j.explore.2024.103039\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Introduction</h3><p>Background: Premenstrual syndrome (PMS) is a common disorder among female population that adversely affects their physical and emotional well-being. Conventional treatments for PMS may have limitations and side effects, prompting a need for complementary therapeutic approaches. This double-blind, randomized, placebo-controlled trial aimed to investigate the efficacy of individualized Homeopathic medicines (IH) in treating PMS symptoms in comparison to placebo (PL).</p></div><div><h3>Methods</h3><p>This study recruited female participants of reproductive age who had been experiencing premenstrual syndrome (PMS) for &gt;3 months, from the Outpatient Department. The participants were randomly assigned to receive either IH or PL. The measured outcomes included the Shortened Premenstrual Assessment Form (SPAF) questionnaire as the primary outcome, and the Premenstrual Tension Syndrome Visual Analogue Scale (PMTS-VAS) and the Premenstrual Tension Syndrome Observer Rating Scale – Revised (PMTS-OR) as secondary outcomes. These measures were assessed at baseline and every month for 3 months.</p></div><div><h3>Results</h3><p>The results showed a statistically significant reduction in total SPAF scores for the IH group compared to the placebo group (<em>F</em> = 11.340; <em>P</em> &lt; 0.001) at month 2 (-5.5 ± 1.8, <em>P</em> = 0.003), and month 3 (-6.6 ± 2.0, <em>P</em> = 0.002). Additionally, there were significant reductions in PMTS-VAS and PMTS-OR scores in the IH compared to placebo group. <em>Natrum muriaticum</em> (<em>n</em> = 4/30, 13.3 %) was the most frequently indicated medicines in the study. Four adverse events (13.33 %) occurred in the IH group, and six adverse events (16.67 %) in the Placebo group, with no serious events reported, and no additional medicinal treatment was required for participants during the study period.</p></div><div><h3>Conclusions</h3><p>Individualized Homeopathic medicines were found to be significantly effective, compared to placebo in reducing PMS symptoms. Further independent replication is warranted to validate and corroborate these findings, as well as to identify the most effective Homeopathic medicines for treating PMS symptoms. Until then, clinicians may consider these findings when exploring personalized and holistic therapeutic strategies for managing PMS.</p></div><div><h3>Trial Registration</h3><p>CTRI/2020/11/028,796, dt. 02/11/2020</p></div>\",\"PeriodicalId\":1,\"journal\":{\"name\":\"Accounts of Chemical Research\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":16.4000,\"publicationDate\":\"2024-08-17\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Accounts of Chemical Research\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1550830724001460\",\"RegionNum\":1,\"RegionCategory\":\"化学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CHEMISTRY, MULTIDISCIPLINARY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Accounts of Chemical Research","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1550830724001460","RegionNum":1,"RegionCategory":"化学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CHEMISTRY, MULTIDISCIPLINARY","Score":null,"Total":0}
引用次数: 0

摘要

导言背景:经前期综合征(PMS)是女性人群中常见的一种疾病,对她们的身心健康造成了不利影响。经前期综合征的传统治疗方法可能存在局限性和副作用,因此需要辅助治疗方法。这项双盲、随机、安慰剂对照试验旨在研究个体化顺势疗法药物(IH)与安慰剂(PL)相比在治疗经前综合征症状方面的疗效。参与者被随机分配接受 IH 或 PL 治疗。测量结果包括作为主要结果的经前期评估简表(SPAF)问卷,以及作为次要结果的经前期紧张综合征视觉模拟量表(PMTS-VAS)和经前期紧张综合征观察者评定量表-修订版(PMTS-OR)。结果表明,与安慰剂组相比,IH 组 SPAF 总分在第 2 个月(-5.5 ± 1.8,P = 0.003)和第 3 个月(-6.6 ± 2.0,P = 0.002)显著降低(F = 11.340; P < 0.001)。此外,与安慰剂组相比,IH组的PMTS-VAS和PMTS-OR评分明显降低。本研究中最常使用的药物是硝酸甘油(4/30,13.3%)。IH组发生了4起不良事件(13.33%),安慰剂组发生了6起不良事件(16.67%),没有严重事件报告,参与者在研究期间不需要额外的药物治疗。为了验证和证实这些研究结果,并确定治疗经前综合征症状最有效的顺势疗法药物,有必要进一步进行独立复制。在此之前,临床医生在探索经前综合征的个性化整体治疗策略时,可以考虑这些研究结果。试验注册CTRI/2020/11/028,796, dt.02/11/2020
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Individualized homeopathic medicines in the treatment of premenstrual syndrome: A double-blind, randomized, placebo-controlled trial

Introduction

Background: Premenstrual syndrome (PMS) is a common disorder among female population that adversely affects their physical and emotional well-being. Conventional treatments for PMS may have limitations and side effects, prompting a need for complementary therapeutic approaches. This double-blind, randomized, placebo-controlled trial aimed to investigate the efficacy of individualized Homeopathic medicines (IH) in treating PMS symptoms in comparison to placebo (PL).

Methods

This study recruited female participants of reproductive age who had been experiencing premenstrual syndrome (PMS) for >3 months, from the Outpatient Department. The participants were randomly assigned to receive either IH or PL. The measured outcomes included the Shortened Premenstrual Assessment Form (SPAF) questionnaire as the primary outcome, and the Premenstrual Tension Syndrome Visual Analogue Scale (PMTS-VAS) and the Premenstrual Tension Syndrome Observer Rating Scale – Revised (PMTS-OR) as secondary outcomes. These measures were assessed at baseline and every month for 3 months.

Results

The results showed a statistically significant reduction in total SPAF scores for the IH group compared to the placebo group (F = 11.340; P < 0.001) at month 2 (-5.5 ± 1.8, P = 0.003), and month 3 (-6.6 ± 2.0, P = 0.002). Additionally, there were significant reductions in PMTS-VAS and PMTS-OR scores in the IH compared to placebo group. Natrum muriaticum (n = 4/30, 13.3 %) was the most frequently indicated medicines in the study. Four adverse events (13.33 %) occurred in the IH group, and six adverse events (16.67 %) in the Placebo group, with no serious events reported, and no additional medicinal treatment was required for participants during the study period.

Conclusions

Individualized Homeopathic medicines were found to be significantly effective, compared to placebo in reducing PMS symptoms. Further independent replication is warranted to validate and corroborate these findings, as well as to identify the most effective Homeopathic medicines for treating PMS symptoms. Until then, clinicians may consider these findings when exploring personalized and holistic therapeutic strategies for managing PMS.

Trial Registration

CTRI/2020/11/028,796, dt. 02/11/2020

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Accounts of Chemical Research
Accounts of Chemical Research 化学-化学综合
CiteScore
31.40
自引率
1.10%
发文量
312
审稿时长
2 months
期刊介绍: Accounts of Chemical Research presents short, concise and critical articles offering easy-to-read overviews of basic research and applications in all areas of chemistry and biochemistry. These short reviews focus on research from the author’s own laboratory and are designed to teach the reader about a research project. In addition, Accounts of Chemical Research publishes commentaries that give an informed opinion on a current research problem. Special Issues online are devoted to a single topic of unusual activity and significance. Accounts of Chemical Research replaces the traditional article abstract with an article "Conspectus." These entries synopsize the research affording the reader a closer look at the content and significance of an article. Through this provision of a more detailed description of the article contents, the Conspectus enhances the article's discoverability by search engines and the exposure for the research.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信